Bailey Health Solutions puts a recognizable monthly figure on its weight-loss program: a regular $389, with $50 off the first month. It also advertises a free initial visit, no contracts, no added fees and no membership fees. For someone comparing treatment budgets, those are useful disclosures. The harder question is what that monthly payment purchases across evaluation, laboratory work, medication, delivery and continuing care—and what happens financially when treatment changes or ends.
This review examines the provider’s public documentation consulted October 19, 2026, rather than a purchased treatment experience. Bailey describes an integrative healthcare practice in St. Augustine, Florida, offering office-based care and telehealth weight-loss visits. Its documented medication offer is an injectable compounded GLP-1 preparation with B-12. The sources explain several steps in care but do not identify the specific active ingredient, pharmacy or complete billing rules. Those gaps matter when comparing the advertised price with a personalized written quote.
At a glance
- Advertised program price
- Compounded GLP-1 with B-12 is advertised at a regular $389 per month, with $50 off the first month and month-to-month pricing.Sources: [5]
- Initial consultation
- The initial visit is advertised as free and includes consultation, questions about the compounded preparation, examination of current physical health and review of recent blood tests.Sources: [5]
- Medication process
- Bailey says it orders and ships medication to the patient’s residence after reviewing blood work and determining that the person is a suitable candidate.Sources: [5]
- Location and reach
- The practice lists a St. Augustine, Florida, office and says medication can ship to most states, without naming those states in the consulted material.
Read the first-month discount separately from the ongoing price
Bailey’s price disclosure has three distinct parts: the initial visit is free, the first program month receives a $50 discount, and the regular program price is $389 per month. The offer specifically concerns compounded GLP-1 with B-12, not an identified FDA-approved branded product. Keeping those elements separate prevents the free consultation or introductory discount from becoming the assumed ongoing cost. The published regular price is the more useful starting point for a continuing-care budget.
The wording is “per month,” not every four weeks. However, the documentation does not define the collection date, whether renewal is automatic or precisely how a billing month maps to a medication shipment. It also does not establish an upfront package payment or a minimum treatment duration. Our explanation of GLP-1 billing intervals provides context for distinguishing a monthly charge from a defined supply period; Bailey’s own quote still needs to settle that relationship.
The provider’s no-added-fees statement is meaningful advertising, but it is not an itemized invoice. There is no published breakdown showing the price of laboratory work, injection materials or shipping within the monthly figure. Nor does the sample explain whether the charge changes with formulation or quantity. Ask for a written total covering the first paid month and the ordinary subsequent month, rather than treating either the discount or the broad fee language as a complete billing specification.
| Item | Documented offer | Still worth confirming |
|---|---|---|
| Initial visit | Free consultation and listed assessment services | Whether any separately ordered testing creates a charge |
| First program month | $50 off the first month | The actual collection date and itemized amount |
| Ongoing program | Regular price of $389 per month | Supply period and any formulation- or quantity-related changes |
| Additional charges | No added fees or membership fees advertised | Written treatment of labs, shipping and injection materials |
| Commitment | No contracts; month-to-month pricing | Cancellation steps, renewal timing and refund rules |
The free visit has a defined scope; laboratory costs do not
The free initial visit is more specifically described than many other parts of the offer. Bailey lists a consultation, answers to questions about compounded GLP preparations with B-12, examination of current physical health and review of recent blood tests. Its process page says the first weight-loss visit can occur in the office or through telehealth and includes discussion of current health, weight-loss goals and previous attempts. That is an assessment opportunity, not a promise that medication will be prescribed.
Laboratory work introduces an important distinction between reviewing existing information and obtaining new testing. Bailey says it will complete a weight-loss panel if blood work has not been completed within the past year. The consulted material does not list the tests in that panel, its cost or whether repeat testing is included in the $389 monthly charge. The free-visit description explicitly includes review of recent tests; it does not separately establish that a new laboratory panel is free.
The next financial question is timing: when, relative to testing and clinical review, does the paid program begin? Bailey says medication is ordered after blood work has been received and reviewed, provided the person is a suitable candidate, but does not publish the corresponding payment sequence. A useful quote should explain any assessment-stage charge if medication is not prescribed. The distinction between an advertised service and a fully itemized inclusion is explored in our guide to what a program price includes.
The medication description is not yet a product specification
The actual offer repeatedly describes compounded GLP or GLP-1 medication with B-12. Although a page title mentions semaglutide, the program description does not establish the specific active ingredient dispensed. It also does not identify the compounding or dispensing pharmacy, its location, concentration, presentation or shipment quantity. The route is clearer: Bailey describes injections and says staff will demonstrate administration in person or through telehealth. Local patients may instead visit the office weekly for their injection.
These details affect what a price comparison can responsibly establish. Without an identified ingredient and formulation, $389 cannot be treated as the price of a particular branded medicine or a directly comparable standardized product. The sources also do not establish why B-12 is included or demonstrate a benefit from that combination. A written medication specification and the pharmacy’s identity would make the quote substantially more useful without requiring a patient to infer product details from promotional terminology.
FDA states that compounded preparations are not FDA approved and do not undergo its premarket review for safety, effectiveness and quality. That status alone does not prove clinical inequivalence or establish whether this provider’s care is appropriate. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Approval attaches to a specific product, not to a clinic, and Bailey’s price does not resolve that clinical distinction.
Delivery is promised, but the shipping responsibilities need detail
Bailey describes a recognizable sequence: consultation, review of blood work, a suitability decision, medication ordering and shipment to the patient’s residence. It says the medication can be shipped to most states. That statement is not a state-by-state availability list, however, and does not establish that a particular resident can receive telehealth evaluation or a prescription. Before paying, an out-of-state patient should obtain confirmation for their location rather than assuming that shipping reach and clinical availability are identical.
The public description does not name a carrier, specify preparation or dispatch times, promise an arrival date or explain tracking. It also does not describe cold-chain procedures or who handles lost, delayed or damaged packages. These are relevant cost questions because an unusable shipment can raise questions about replacement charges and interrupted service. Bailey’s no-added-fees language does not, by itself, explain responsibility for every delivery problem; written replacement and contact procedures would be more informative.
FDA’s delivery advice supplies an important boundary that the provider’s general shipping statement does not: do not use an injectable GLP-1 drug that arrives warm or with insufficient refrigeration, and contact the provider or dispensing pharmacy. That is not an allegation about Bailey’s shipments. It is a reason to obtain the pharmacy name and a usable delivery-support contact before shipment, along with an explanation of how product concerns are assessed and how replacement decisions affect the bill.
Follow-up is part of the offer, but its schedule is flexible
Bailey says a practitioner will closely monitor patients during the program and tailor treatment to individual needs. It also advertises weekly visits as available but not required. Those statements distinguish the program from a medication-only shipment, while leaving the minimum follow-up schedule unclear. The sources do not identify a required monthly appointment, a fixed remote check-in format or the number of clinician contacts associated with each payment. Optional weekly access should not be read as a weekly attendance requirement.
The program includes an injection demonstration, and it describes a later conversation with a health coach about a personalized diet plan after the target dose is reached. These are specific service features, but the documentation does not detail the duration or frequency of coaching. Nor does it identify which staff member provides each follow-up service. For budgeting, ask whether optional office visits, telehealth follow-ups and coaching all fall under the advertised no-added-fees arrangement, and request any exceptions in writing.
Support is described as available by calling or texting the office at any time, with a promise to be responsive. This does not establish round-the-clock clinical staffing or a guaranteed response time. The listed office hours are Monday through Friday, 9 a.m. to noon and 2 p.m. to 6 p.m. NIDDK emphasizes that follow-up concerns treatment response and tolerability, not simply renewed payments; Bailey’s contact offer is therefore useful, but its practical response boundaries still deserve clarification.
Month-to-month pricing does not answer cancellation or insurance questions
“No contracts” and “month to month pricing” are the provider’s express terms for the offer. They are helpful signals about how Bailey markets the commitment, but they do not provide an operational cancellation policy. The consulted pages do not specify a cancellation channel, notice deadline, last billing date, automatic-renewal mechanism or refund boundary. It would be inappropriate to invent a minimum commitment, but equally inappropriate to infer that every payment is refundable or that stopping messages stops charges.
The terms explain how to stop SMS communications by replying STOP. That is a communications opt-out, not a documented treatment cancellation method. A patient should separately establish how to stop future program billing and what happens to medication already ordered or dispensed. Our guide to cancellation and refunds explains why those are separate questions. Bailey’s public documentation does not settle either the treatment-cancellation procedure or whether unused time, supplies or undelivered medication qualify for reimbursement.
Insurance is another area where the practice’s general messaging should not be expanded into a program-specific promise. The homepage says many insurances are accepted and payment plans are available, but does not expressly connect either statement to the GLP-1 offer. There is no confirmed insurer list, medication coverage arrangement or authorization service in the supplied evidence. NIDDK notes that weight-management medication coverage varies by plan; accepting insurance for a consultation does not establish coverage for the medicine or the monthly program.
Know the practice, the professional and the enrollment contact
Bailey describes its broader business as integrative healthcare combining medical and natural approaches. It lists an office at 224 Southpark Circle East, St. Augustine, Florida 32086, and telephone number (904) 342-4941. Its contact form accepts a name, email address, telephone number and service of interest for a response. These are concrete access paths, although the material does not confirm a patient portal, Spanish-language care, interpretation services or clinical support beyond the published office schedule.
The team page lists Jason Bailey, D.C., a chiropractor whom the site says has practiced since 1998 and moved the practice from Miami in 2015. It also lists Chastity Haltam, APRN, an advanced practice registered nurse; Rachel Lahav, PA, a physician assistant whose listed areas include weight loss; and Zehra Cumber, D.O., an osteopathic physician. These are the site’s credential descriptions, not independently verified licenses. The pages do not identify which professional evaluates or prescribes for an individual GLP-1 patient.
Enrollment also presents an identity question worth resolving without assuming misconduct. The terms identify Bailey Health Solutions and carry an effective date of October 1, 2023, while contact-form marketing consent names Bailey Spine & Wellness LLC. The relationship between those names is not explained in the supplied material. Before providing payment details, ask which entity provides care, bills for the program and sends communications. SMS consent is expressly not required to receive services, a useful distinction when completing the contact process.
Use the free consultation to turn the advertisement into a written quote
Bailey’s candidate examples include people with at least 25 pounds to lose, PCOS or type 2 diabetes, as well as people ready to change their diet or struggling to maintain weight loss. These are the provider’s broad examples, not automatic approvals or a complete clinical screening protocol. A separate inconsistency concerns age: the homepage says “All Ages Welcome,” while the terms state that services, the website and communications are not intended for people under 18. The sources do not explain the differing scope.
The consultation is the logical point to request one written document identifying the medication and pharmacy, available state, first charge, ordinary monthly charge, laboratory responsibilities, supplied quantity and cancellation process. It should also distinguish optional visits from required monitoring and explain how delivery concerns are handled. Our prepayment question checklist provides a framework, but the answers must come from Bailey. A completed quote would be more decision-useful than either the low-friction marketing language or assumptions that every missing detail represents an extra fee.
Privacy documentation offers some practical protections relevant to that conversation. Bailey says it does not sell, rent or share mobile numbers or SMS opt-in data for third-party marketing or promotional purposes. It recognizes access to an electronic health record, directing that record to a third party and reasonable requests for privacy-preserving communications. The site also discloses cookies and tracking technologies for website experience and marketing. These statements describe documented policies, not a verification of implementation or the completeness of the privacy framework.
Questions & answers
What does Bailey advertise for the first month and later months?
The compounded GLP-1 with B-12 program advertises $50 off the first month and a regular price of $389 per month. The initial visit is separately advertised as free. The sources do not define the collection date, automatic-renewal arrangement or medication quantity associated with each monthly payment. Request a written first-payment total and subsequent billing schedule.
Are blood tests included in the free consultation?
Review of recent blood tests is explicitly included. Bailey says it will complete a weight-loss panel if blood work has not been completed within the past year, but the consulted material does not state the panel’s price or confirm that new testing is free. It also does not describe the cost of repeat testing during treatment.
Which medicine and pharmacy would supply treatment?
The offer describes an injectable compounded GLP-1 preparation with B-12. Despite a semaglutide reference in a page title, the program description does not establish the actual active ingredient, concentration or pharmacy. Ask Bailey for those details before payment. FDA approval of a branded product would not extend to an unidentified compounded preparation offered by the practice.
Can I use Bailey entirely through telehealth?
Bailey describes telehealth for the first visit and the injection demonstration, followed by home shipment for suitable candidates. It says shipment is possible to most states but does not identify them. The sources therefore do not confirm fully remote availability for every address. Local patients also have an option to attend the St. Augustine office weekly for injections.
Does no contracts mean I can obtain a refund whenever I stop?
No refund entitlement is established by that wording. Bailey advertises no contracts and month-to-month pricing, but the consulted documentation does not explain cancellation deadlines, future-charge prevention or refunds. Replying STOP ends SMS communications under the messaging terms; it is not a documented cancellation of treatment. Ask for separate written instructions covering program cancellation and money already collected.
Will insurance or a payment plan cover the $389 charge?
The homepage advertises acceptance of many insurances and availability of payment plans, but does not specifically attach those options to GLP-1 treatment. No particular plan, covered medication or financing arrangement is confirmed here. Ask Bailey which charges can be submitted to insurance and confirm benefits directly with your plan rather than assuming the monthly program is covered.
Our assessment
Bailey Health Solutions documents a tangible service offering: a free initial assessment, a regular $389 monthly compounded GLP-1 with B-12 program, an introductory discount, home shipment, injection instruction and optional weekly visits. Those specifics make the offer more informative than a price-free consultation funnel. Its main cost limitation is not an absence of advertised pricing; it is the missing connection between that price and a fully specified medication, laboratory arrangement, shipment and exit policy. The sources do not establish provider-specific treatment outcomes or verify the advertised service experience. For a prospective patient, the most useful next step is to use the free consultation to obtain an itemized written quote and clear clinical and pharmacy responsibilities before deciding whether the program fits their care needs and budget.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Bailey Health Solutions — official website ↗
- Bailey Health Solutions — contact ↗
- Bailey Health Solutions — glp1weightloss ↗
- Bailey Health Solutions — terms and conditions ↗
- Bailey Health Solutions — meet the team ↗
- Bailey Health Solutions — notice of privacy practices ↗